Tuesday, May 20, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > CEO Life > Health > Study: Mounjaro leads to greater weight loss than Ozempic

Study: Mounjaro leads to greater weight loss than Ozempic

in Health
Study: Mounjaro leads to greater weight loss than Ozempic
Share on LinkedinShare on WhatsApp

A major head-to-head study found that people lost significantly more weight with Eli Lilly’s diabetes drug Mounjaro compared to Novo Nordisk’s Ozempic, with similar side effects, drop-out rates, and diabetes benefits. Both drugs belong to the GLP-1 class, but Mounjaro, which contains tirzepatide, also marketed as Zepbound for weight loss, has an additional action enhancing its effectiveness. Previous studies had suggested tirzepatide led to more weight loss than semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss at a higher dose.

The new study, published in JAMA Internal Medicine, analyzed data from more than 18,000 patients who started taking one of the two medications between May 2022 and September 2023, using electronic health records from Truveta, a collective of health systems with access to data on over 100 million patients. The study focused on people prescribed these drugs for type 2 diabetes, as tirzepatide was not yet approved for weight loss at the time.

By November of last year, more than half of the participants had stopped taking the medications, with 56% discontinuing tirzepatide and 53% stopping semaglutide, primarily due to gastrointestinal side effects like vomiting and nausea. The study did not indicate whether those who discontinued the drugs regained the weight they had lost.

Tags: CEOEli LillyHealthJAMA Internal MedicineNovo NordiskOzempicSemaglutideTirzepatideWeight Loss

Related Posts

Texas TikTok ban challenged on academic freedom clause
Health

TikTok adds meditation tools for teen sleep health

The best exercises for your bones
Health

The best exercises for your bones

6 Health Benefits of Manuka Honey, Based on Science
Health

6 Health Benefits of Manuka Honey, Based on Science

Can chocolate ever be healthy? A dietitian breaks it down
Food

Can chocolate ever be healthy? A dietitian breaks it down

25 years on, the unsettling morning routine in ‘American Psycho’ is normal
Health

25 years on, the unsettling morning routine in ‘American Psycho’ is normal

These neurons have food on the brain
Health

How Food Affects Your Productivity (& What You Can Do About It)

Should You Be Wary of Sugar in Fruit?
Health

Should You Be Wary of Sugar in Fruit?

Remarkable health benefits of drinking black coffee
Health

Remarkable health benefits of drinking black coffee

8 Tips for a Healthier Spring
Health

8 Tips for a Healthier Spring

Research-Backed Tips for Living a Good Life in 2025‌‌
Health

Research-Backed Tips for Living a Good Life in 2025‌‌

No Result
View All Result

Recent Posts

  • Diageo predicts $150 million tariff impact
  • We Expect to Be Rewarded for Results, Not Hard Work
  • How Trump’s crypto business partners left their old clients in the lurch
  • Bessent says some tariff rates to return to ‘reciprocal’
  • Regeneron to buy 23andMe in $256 million deal

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.